| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000002557 |
| Receipt No. | R000003077 |
| Official scientific title of the study | Multicenter randomized phase III study of adding Bevacizumab 5mg/kg or 10mg/kg to FOLFIRI in advanced colorectal cancer who have failed prior Bevacizumab plus Oxaliplatin-based therapy. |
| Date of disclosure of the study information | 2009/09/30 |
| Last modified on | 2018/09/20 (Ver. 20) |
| Basic information | ||
| Official scientific title of the study | Multicenter randomized phase III study of adding Bevacizumab 5mg/kg or 10mg/kg to FOLFIRI in advanced colorectal cancer who have failed prior Bevacizumab plus Oxaliplatin-based therapy. | |
| Title of the study (Brief title) | Phase III study of Bevacizumab 5mg/kg or 10mg/kg to FOLFIRI in advanced CRC who have failed prior Bevacizumab plus Oxaliplatin-based therapy. | |
| Region |
|
|
| Condition | ||||||||
| Condition | advanced colorectal cancer | |||||||
| Classification by specialty |
|
|||||||
| Classification by malignancy | Malignancy | |||||||
| Genomic information | NO | |||||||
| Objectives | |
| Narrative objectives1 | Multicenter randomized phase III study of adding Bevacizumab 5mg/kg or 10mg/kg to FOLFIRI in advanced colorectal cancer who have failed prior Bevacizumab plus Oxaliplatin-based therapy. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase III |
| Assessment | |
| Primary outcomes | progression free survival |
| Key secondary outcomes | >Overall survival
>Overall survival from first line Second progression free survival (progression free survival from first line) >Response rate >Time to treatment failure >Safety |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | YES |
| Dynamic allocation | YES |
| Institution consideration | Institution is considered as adjustment factor in dynamic allocation. |
| Blocking | NO |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | FOLFIRI plus bevacizumab 5mg/kg is treated until progression.
|
|
| Interventions/Control_2 | FOLFIRI plus bevacizumab 10mg/kg is treated until progression. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1) Disease progression(PD) or difficult to continue for other reason after chemotherapy with bevacizumab as 1st line Oxaliplatin containing regimen
(with measurable lesions in RECIST criteria) (2) Oxaliplatin and bevacizumab were administrated for more than 4 times in 1stline (3) Colorectal cancer, cytologically and/or histrogically (4) Written informed consents (5) Age: 20 years old and above (6) Performance Status(ECOG):0~1 (7) Life expectancy estimated >= 3 months (8) Sufficient organ functions |
|||
| Key exclusion criteria | (1) Previously irinotecan treatment
(2) Administering transfusion/ hematopoietic factor or antithrombotic drug within 14 days (3) Serious renal dysfunction (4) Serious drug hypersensitivity or a history of drug allergy (5) Active concomitant malignancy (6) Active infections (7) Symptomatic or asymptomatic but treated heart disease (8) History of thrombosis, interstitial pneumonitis, pulmonary fibrosis or high-grade pulmonary emphysema (9) Fresh hemorrhage from digestive tube, intestines tube paralysis, intestinal obstruction and peptic ulcer (10) Pleural effusion, peritoneal fluid and pericardial fluid (11) Symptomatic brain metastasis (12) History of mental disturbances or cerebrovascular accident (13) High blood pressure and diabetic that cannot be controlled (14) Uncontrolled diarrhea (15) Serious non-healing wound and/or major surgical procedure within 4weeks prior to enroll in this study (16) Traumatic fracture of unrecovery (17) Bleeding tendency and anti-platelets therapy (including aspirin and NSAIDS) (18) Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers (19) Need to treatment with atazanavir sulfate (20) Paralyzed bowel (21) Other conditions not suitable for this study |
|||
| Target sample size | 370 | |||
| Research contact person | |
| Name of lead principal investigator | Hideyuki Mishima |
| Organization | Aichi Medical University |
| Division name | Cancer Center |
| Address | 1-1, Yazakokarimata, Nagakute, Aichi |
| TEL | 0561-62-3311 |
| hmishima@aichi-med-u.ac.jp | |
| Public contact | |
| Name of contact person | Chigusa Abe |
| Organization | Epidemiological and Clinical research Information Network (ECRIN) |
| Division name | Data Center |
| Address | 21-7 Shogoinn Sakyo-ku, Kyoto |
| TEL | 075-762-1227 |
| Homepage URL | |
| chigusa.abe@ecrin.or.jp | |
| Sponsor | |
| Institute | Epidemiological and Clinical research Information Network (ECRIN) |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Epidemiological and Clinical research Information Network (ECRIN) |
| Organization | |
| Division | |
| Category of Funding Organization | Non profit foundation |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | |
| Results | Results:
Three hundred and eighty-seven patients were randomized between September 2009 and January 2012 from 100 institutions in Japan. Baseline patient characteristics were well balanced between the two groups. Efficacy was evaluated in 369 patients (5 mg/kg, n = 181 and 10 mg/kg, n = 188). Safety was evaluated in 365 patients (5 mg/kg, n = 180 and 10 mg/kg, n = 185). The median PFS was 6.1 versus 6.4 months (hazard ratio, 0.95; 95% confidence interval [CI] 0.75-1.21; P = 0.676), and median TTF was 5.2 versus 5.2 months (hazard ratio, 1.01; 95% CI 0.81-1.25; P = 0.967), respectively,for the bevacizumab 5 and 10 mg/kg groups. Follow-up of OS is currently ongoing. Adverse events, including hypertension and hemorrhage, occurred at similar rates in both groups. |
| Other related information | Annals of Oncology 26: 1427-1433, 2015
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after firstline bevacizumab plus oxaliplatin-based therapy: therandomized phase III EAGLE study S. Iwamoto1,, T. Takahashi, H. Tamagawa, M. Nakamura, Y. Munemoto, T. Kato, T. Hata,T. Denda, Y. Morita, M. Inukai, K. Kunieda, N. Nagata, K. Kurachi, K. Ina14, M. Ooshiro,T. Shimoyama, H. Baba, K. Oba, J. Sakamoto & H. Mishima |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003077 |